Abstract
A proportion of patients surviving acute COVID-19 infection develop post-COVID syndrome (long COVID) encompassing physical and neuropsychiatric symptoms lasting longer than 12 weeks. Here we studied a prospective cohort of individuals with long COVID compared to age/gender matched subjects without long COVID (from the ADAPT study), healthy donors and individuals infected with other non-SARS CoV2 human coronaviruses (the ADAPT-C study). We found highly activated innate immune cells and an absence of subsets of un-activated naïve T and B cells in peripheral blood of long COVID subjects, that did not reconstitute over time. These activated myeloid cells may contribute to the elevated levels of type I (IFN-β) and III interferon (IFN-λ1) that remained persistently high in long COVID subjects at 8 months post-infection. We found positive inter-analyte correlations that consisted of 18 inflammatory cytokines in symptomatic long COVID subjects that was not observed in asymptomatic COVID-19 survivors. A linear classification model was used to exhaustively search through all 20475 combinations of the 29 analytes measured, that had the strongest association with long COVID and found that the best 4 analytes were: IL-6, IFN-γ, MCP-1 (CCL2) and VCAM-1. These four inflammatory biomarkers gave an accuracy of 75.9%, and an F1 score of 0.759, and have also previously been associated with acute severe disease. In contrast, plasma ACE2 levels, while elevated in the serum of people previously infected with SARS-CoV-2 were not further elevated in subjects with long COVID symptoms. This work defines immunological parameters associated with long COVID and suggests future opportunities to prevention and treatment.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ACTRN12620000554965
Funding Statement
We appreciate grant support from the St Vincents Clinic Foundation - the Curran Foundation, the Rapid Response Research Fund (UNSW) - the Medical Research Futures Fund (Australia) - NHMRC programme grant APP 1055214 (LMB) - Medical Research Future Fund award GNT 1175865 - - Austin Medical Research Foundation Grant - the Victorian Government - MRFF Award (2005544) - NHMRC program grant (1149990) - NHMRC Fellowships 1136322 and 1123673
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
- The ADAPT study was approved by the St Vincents Hospital Research Ethics Committee (2020/ETH00964) and is a registered trial (ACTRN12620000554965) - ADAPT-C sub study was approved by the same committee (2020/ETH01429) - All data were stored using REDCap electronic data capture tools - Unexposed healthy donors were recruited through St Vincents Hospital and was approved by St Vincents Hospital Research Ethics Committee (HREC/13/SVH/145) - The University of Melbourne unexposed donors were approved by Medicine and Dentistry HESC-Study ID 2056689. All participants gave written informed consent.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Source data files will be uploaded upon submission to intended journal
